What is the difference between AOD-9604 and IGF-1?

AOD-9604: AOD-9604 stimulates lipolysis and inhibits lipogenesis through mechanisms believed to be independent of the insulin-like growth factor pathway. IGF-1: Binds IGF-1R with high affinity, activating PI3K/Akt and MAPK pathways promoting protein synthesis, satellite cell activation, and glucose uptake.

Is IGF-1 FDA approved?

IGF-1 is FDA approved (FDA status current as of 2005-08-30). This regulatory status is provided for research and educational context only.

How is AOD-9604 administered in research settings?

In research settings, AOD-9604 is typically administered via the subcutaneous or oral routes. PeptideBase does not provide dosing or administration instructions.

How is IGF-1 administered in research settings?

In research settings, IGF-1 is typically administered via the subcutaneous or intramuscular routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›AOD-9604 vs IGF-1

Peptide Comparison

AOD-9604 vs IGF-1

Name: AOD-9604 vs IGF-1 — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are GH / IGF Axis peptides.

AOD-9604

Advanced Obesity Drug 9604

Fat LossResearch Only

Half-life: 30–60 minutes

197 providers listed

Full AOD-9604 profile →

IGF-1

Insulin-like Growth Factor 1

PerformanceFDA ApprovedResearch Only

21 providers listed

Full IGF-1 profile →

Bottom line

IGF-1 is FDA-approved, while AOD-9604 is nomination withdrawn — the clearest structural difference between them.

Quick Verdict

AOD-9604

Half-life

30–60 minutes

IGF-1

Half-life

—

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	IGF-1
Further along in FDA review	IGF-1
Oral administration option	AOD-9604
Lower typical price per mg	AOD-9604
More provider options (197 vs 21)	AOD-9604

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

AOD-9604

IGF-1

Mechanism Family

GH / IGF Axis

Half-life

30–60 minutes

—

FDA Status

nomination withdrawn

approved

Admin Routes

subcutaneous, oral

subcutaneous, intramuscular

Availability

Research Only

Providers

197 listed

21 listed

FDA Update

—

Aug 2005

Avail. Notes

HGH fragment 176-191. Drug development terminated 2007 (Phase 3 failure). FDA GRAS notice GRN 000792 for food ingredient use only — not a drug approval. No active NDA. Research chemical.

FDA-approved: Increlex (mecasermin, recombinant human IGF-1), Drugs@FDA application 021839.

Research Evidence

AOD-9604

Animal · 1 key study · dated evidence base — most recent 2001

IGF-1

Cohort study · 1 key study · most recent 2026

Research Citations

AOD-9604

Animal2001 · Endocrinology

The effect of the growth hormone fragment AOD9604 on adipose tissue

IGF-1

Cohort2026 · Pituitary

Speckle-tracking echocardiography reveals the synergistic impact of GH/IGF-1 excess and metabolic dysregulati…

About AOD-9604

AOD-9604 stimulates lipolysis and inhibits lipogenesis through mechanisms believed to be independent of the insulin-like growth factor pathway. It appears to mimic the fat-metabolising action of growth hormone without triggering the proliferative effects associated with full GH or GH-releasing peptides. Oral bioavailability has been observed in some formulations, making it of interest for non-injectable protocols.

Research Areas

selective fat tissue lipolysis via GH C-terminal fragment mechanismadipose metabolism stimulation without IGF-1 elevationoriginally developed to isolate GH lipolytic effect from growth effectssubcutaneous injection — reconstitution with bacteriostatic water required

About IGF-1

Binds IGF-1R with high affinity, activating PI3K/Akt and MAPK pathways promoting protein synthesis, satellite cell activation, and glucose uptake. Much shorter half-life (~15 min) than the LR3 analog (~20-30 hr) due to binding protein interactions.

Research Areas

muscle growthrecoveryfat metabolismtissue repairGH axis

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

AOD-9604

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

IGF-1

Absolute Contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Suggested Monitoring

Under clinical review

Being verified by our medical team before we display monitoring guidance for this peptide.

Price (per mg)

AOD-9604

$9.00/mg

$7.71 – $11.85 range

45 vendors

View price index →Find providers →

IGF-1

$54.33/mg

$29.30 – $73.44 range

8 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

AOD-9604

197 listed

Browse directory →

Providers offering

IGF-1

21 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More GH / IGF Axis Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated August 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). AOD-9604 vs IGF-1 — Per-mg Price Comparison. Retrieved September 12, 2026, from https://peptidebase.io/peptides/compare/aod-9604/igf-1

https://peptidebase.io/peptides/compare/aod-9604/igf-1 Methodology License Download JSON Download CSV